DFTX stock forecast, quote, news & analysis
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction... Show more
Why Definium Therapeutics (DFTX) Stock Is Up +11% in the Last 30 Days
Key Takeaways
- Definium Therapeutics (DFTX) shares gained approximately 11% over the past 30 days, driven by advancing clinical milestones for its lead candidate DT120 ODT and favorable sector sentiment.
- Over the last quarter, DFTX surged roughly 30%, reflecting sustained momentum from the Trump administration's executive order accelerating psychedelic medical research and multiple analyst initiations with bullish price targets.
- The company dosed the first patient in Ascend, its second Phase 3 pivotal study of DT120 ODT in major depressive disorder (MDD), reinforcing confidence in the late-stage pipeline.
- Analyst consensus remains a Strong Buy with an average 12-month price target of approximately $39.87, implying significant upside from current levels.
- Three Phase 3 topline data readouts for DT120 ODT are expected in the coming months, representing major binary catalysts for the stock.
- Definium held $373.4 million in cash and equivalents as of March 31, 2026, providing a runway into 2028 and reducing near-term dilution risk.
Definium Therapeutics (DFTX) Company Overview and Market Position
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing next-generation therapeutics for psychiatric and neurological disorders. Formerly known as Mind Medicine (MindMed) Inc., the company rebranded in January 2026 and now trades on Nasdaq under the ticker DFTX. Headquartered in New York, Definium applies scientific rigor to psychedelic-inspired compounds, with the goal of delivering treatments that address underlying causes of brain health disorders rather than merely managing symptoms.
The company's lead candidate, DT120 ODT (lysergide tartrate), is an orally disintegrating tablet formulation of LSD being evaluated in four Phase 3 clinical trials — two each for generalized anxiety disorder (GAD) and major depressive disorder (MDD). DT120 ODT has received FDA Breakthrough Therapy Designation for GAD, underscoring its potential to address significant unmet medical needs. Definium is also advancing DT402, a Phase 2a candidate for autism spectrum disorder. With no approved products or revenue yet, the company's valuation is entirely driven by clinical progress, regulatory milestones, and the broader investment narrative around psychedelic medicine.
Definium Therapeutics (DFTX) Stock Price Performance: Last 30 Days vs. Quarter
DFTX shares climbed approximately 11% over the trailing 30-day period, extending a broader rally that has defined the stock's trajectory in recent months. The move reflects a combination of company-specific clinical execution and sustained investor enthusiasm for the psychedelic therapeutics sector. Trading volume has remained elevated relative to historical averages, indicating robust institutional and retail participation.
Zooming out to the quarterly view, DFTX has gained roughly 30%, building on momentum that began earlier in 2026. The stock has benefited from a series of positive developments, including the White House executive order on psychedelic research, multiple Wall Street analyst initiations at Outperform or Buy ratings, and the company's well-received Investor and Analyst Day in April. The 52-week range spans from $6.35 to $26.25, highlighting both the stock's volatility and the magnitude of its recovery from mid-2025 lows.
What Drove DFTX Stock Price in the Last 30 Days
Several verified catalysts contributed to DFTX's 11% advance over the past 30 days. The most significant was the announcement that the first patient had been dosed in Ascend, the second Phase 3 pivotal study of DT120 ODT in major depressive disorder. This milestone confirmed that the company's MDD program is progressing on schedule and expanded the dataset that will ultimately support regulatory submissions.
Definium also reported first-quarter 2026 financial results, posting a net loss of $77.1 million, or $0.71 per share, while reiterating that its cash position of $373.4 million funds operations into 2028. Although the loss was wider than consensus estimates, the market focused on the forward-looking clinical catalysts rather than the near-term burn rate. Piper Sandler subsequently adjusted its price target to $48 from $49 while maintaining an Overweight rating.
Broader sector tailwinds also played a role. The psychedelic biotech space continued to attract attention following the Trump administration's executive order fast-tracking research into psychedelic compounds for mental health conditions. Definium's participation in the Jefferies Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference provided management with platforms to reinforce the DT120 ODT clinical narrative and commercial strategy, further supporting positive sentiment.
What Drove DFTX Stock Performance Over the Last Quarter
DFTX's approximately 30% quarterly gain was shaped by a confluence of macro and company-specific drivers. The single most impactful event was the White House executive order signed in April, which directed federal agencies to accelerate research, development, and responsible access to innovative mental health treatments, including psychedelic medicines. Definium publicly applauded the order, and the stock surged alongside peers such as CMPS and ATAI.
On the corporate front, Definium hosted its Investor and Analyst Day in late April, where management detailed the DT120 ODT clinical advancement and commercial strategy. The company outlined three anticipated Phase 3 topline readouts, expanded the pipeline into PTSD with the planned Phase 3 Haven study, and emphasized commercial readiness modeled on the existing esketamine (SPRAVATO) infrastructure. Several Wall Street firms — including Stifel, Piper Sandler, Wolfe Research, and Jefferies — initiated coverage with Buy or Outperform ratings and price targets ranging from $25 to $49 during the quarter, reflecting growing institutional conviction in the psychedelic psychiatry thesis.
Trending AI Robots
In a market environment where biotech stocks can swing dramatically on clinical data and regulatory news, traders increasingly turn to technology-driven tools for timely decision-making. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to navigate thousands of tickers across diverse market conditions. Only the top-performing and most relevant bots appear in this section, each employing distinct strategies, timeframes, and performance metrics tailored to different trading styles. Whether focused on momentum, swing trading, or longer-term positioning, these bots offer traders a data-driven approach to identifying opportunities. Exploring the Trending AI Robots page can help investors discover automated strategies aligned with their objectives.
DFTX Stock Forecast Drivers: What Investors Should Watch Next
The most critical catalysts for DFTX in the near term are the three upcoming Phase 3 topline data readouts for DT120 ODT. The Voyage study in GAD is expected to report in early Q3 2026, followed by the Emerge study in MDD and the Panorama study in GAD later in the year. Positive results could position Definium for New Drug Application (NDA) submissions and fundamentally transform the company's valuation. Conversely, disappointing data would likely trigger significant downside given the binary nature of biotech clinical outcomes.
Beyond clinical data, investors should monitor regulatory developments in the psychedelic space, including FDA guidance on trial design and scheduling considerations. The company's cash runway into 2028 provides a buffer, but the pace of R&D spending and any potential capital-raising activities will remain in focus. Competitive dynamics from other psychedelic and CNS-focused developers, as well as broader macroeconomic factors affecting the biotechnology sector, will also influence DFTX's trajectory in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DFTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for DFTX turned positive on June 11, 2026. Looking at past instances where DFTX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on DFTX as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
DFTX moved above its 50-day moving average on May 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5 3-day Advance, the price is estimated to grow further. Considering data from situations where DFTX advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 190 cases where DFTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DFTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DFTX broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DFTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.347) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). DFTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DFTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement